Prophylaxis of Hepatitis B Virus Recurrence After Liver Transplantation

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Entecavir demonstrated superior virologic and biochemical benefits over lamivudine and adefovir. The investigators evaluated the effect of entecavir combined Hepatitis B immune globulin (HBIG) with lamivudine or adefovir or both combined HBIG in Chinese liver transplantation patients with Hepatitis B Virus (HBV) related diseases.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shanghai Jiao Tong University School of Medicine
• Collaborator: Zhejiang University
• Treatments: Adefovir; Adefovir dipivoxil; Entecavir; Lamivudine

Criteria

Inclusion Criteria:

1. patients into the transplant waiting list with HBV-related liver disease.

2. HBsAg-positive.

3. serum HBV-DNA negative.

4. no HCV, HDV and HIV co-infection.

5. without renal dysfunction.

6. No lamivudine, adefovir and entecavir drug allergy history.

7. no HBV-YMDD mutation for patients who have a long-term use of lamivudine.

Exclusion Criteria:

1. patients with HBV-related hepatocellular carcinoma beyond Milan criteria.

2. HBsAg-negative.

3. serum HBV-DNA positive.

4. HCV, HDV and HIV co-infection.

5. patients with severe renal dysfunction or failure.

6. lamivudine, adefovir and entecavir drug allergy history.

7. HBV-YMDD mutation for patients who have a long-term use of lamivudine.